Differences in serum concentration with valproate oral solution versus delayed-release divalproex in an adherent patient

Author:

Davis Erica A. K.1ORCID

Affiliation:

1. 2 Springfield Hospital Center, Sykesville, Maryland

Abstract

Abstract Background Several different formulations of valproic acid derivatives are available in the United States. Although these formulations have different absorption characteristics, they are believed to be interchangeable, with the exception of the extended-release product. Case Report A 31-year-old African American man with schizoaffective disorder was started on fluphenazine concentrate and valproate oral solution on admission to an inpatient unit. A 12-hour steady-state concentration, drawn on 1000 mg/day, resulted in 40.8 mg/L, and the dose continued to be titrated. Despite increasing doses, confirmed medication adherence, and accurate lab sampling, his concentrations remained low: 60.3 and 60.1 mg/L on 1500 mg/day, and 65.6 mg/L on 1750 mg/day. He was switched to divalproex delayed-release tablets, and his dose was increased to 2000 mg/day. Follow-up 12-hour steady-state concentrations were significantly higher, at 126.6 and 113.8 mg/L. It is theorized that the formulation of divalproex/valproic acid is what contributed to these differences in concentrations. Discussion Valproic acid formulations are considered to be interchangeable, and several studies have demonstrated that chronic psychiatric inpatients stabilized on delayed-release divalproex may be safely switched to valproate oral solution without changes in psychiatric stability. This case demonstrates a significant difference in serum drug concentrations when switching from valproate oral solution to divalproex delayed-release tablets.

Publisher

College of Psychiatric and Neurologic Pharmacists (CPNP)

Subject

Pharmacology (medical),Neurology (clinical),General Pharmacology, Toxicology and Pharmaceutics,Neuropsychology and Physiological Psychology

Reference7 articles.

1. Aurobindo Pharma Limited. Depakote (divalproex) tablet, delayed release [Internet]. Bethesda (MD): National Library of Medicine (US); 1989 [revised 2022 Mar; cited 2022 Nov 10]. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dbd47222-14f1-4588-a009-9b81b55ca60d

2. Distinct absorption characteristics of oral formulations of valproic acid/divalproex available in the United States;Dutta;Epilepsy Res,2007

3. Bioavailability of valproic acid under fasting/nonfasting regimens;Chun;J Clin Pharmacol,1980

4. Substitution of immediate-release valproic acid for divalproex sodium for adult psychiatric inpatients;Sherr;Psychiatr Serv,1998

5. Dosing differences between valproic acid concentrate and divalproex sodium: a case report;Coffey;J Clin Psychiatry,2004

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3